Hangzhou Coco Healthcare Products Co., Ltd. Class A

Hangzhou Coco Healthcare Products Co., Ltd. Class A

SSZSE:301009
7.97
CNY
-0.20
(-2.45%)
-0.01EPS
2.51BMarket Cap
Apr 26Next Earn

Total Valuation

CNY

As of September 30, 2026, Hangzhou Coco Healthcare Products Co., Ltd. Class A carries a market capitalization of 2.51B, placing it among publicly traded companies globally. Its enterprise value stands at 1.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.51B
Enterprise Value1.95B

Important Dates

Hangzhou Coco Healthcare Products Co., Ltd. Class A's next confirmed earnings release is scheduled for April 26, 2027.

Earnings Date4/26/2027

Share Statistics

As of September 30, 2026, Hangzhou Coco Healthcare Products Co., Ltd. Class A has 271.86M shares outstanding.

Shares Outstanding271.86M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 2.01, and the price-to-book ratio stands at 1.94.

PS Ratio2.01
PB Ratio1.94
P/TBV Ratio2.09

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 1.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.95B versus a market cap of 2.51B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.59

Financial Position

As of September 30, 2026, Hangzhou Coco Healthcare Products Co., Ltd. Class A maintains a current ratio of 1.73, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.51, indicating elevated leverage, while an interest coverage ratio of -2.04 demonstrates limited ability to service its debt obligations.

Current Ratio1.73
Quick Ratio1.13
Debt / Equity19.51
Debt / EBITDA-36.27
Interest Coverage-2.04

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hangzhou Coco Healthcare Products Co., Ltd. Class A posted a negative return on equity (ROE) of -0.39, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.24, reflecting losses generated across the asset base. The company generates approximately 1.62M in revenue per employee across its workforce of 756.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.14 indicates how many times Hangzhou Coco Healthcare Products Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.24
Revenue Per Employee1.62M
Employee Count756.00
Inventory Turnover6.14

Taxes

CNY

Over the twelve months ended September 30, 2026, Hangzhou Coco Healthcare Products Co., Ltd. Class A recorded an income tax benefit of -5.81M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -9.01M and -5.09M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-5.81M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hangzhou Coco Healthcare Products Co., Ltd. Class A's stock has declined approximately 44.92% over the past 52 weeks. The 50-day moving average sits at 8.75, while the 200-day moving average is 10.14.

52-Week Price Change-44.92%
50-Day Moving Average8.75
200-Day Moving Average10.14

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hangzhou Coco Healthcare Products Co., Ltd. Class A generated 1.23B in revenue and converted that into -5.09M in net income, yielding earnings per share of -0.01. EBITDA reached -7.41M, while operating income came in at 20.88M.

Revenue1.23B
Gross Profit287.54M
Operating Income20.88M
Pretax Income-9.01M
Net Income-5.09M
EBITDA-7.41M
EBIT-7.41M
Earnings Per Share (EPS)-0.01

Balance Sheet

CNY

As of September 30, 2026, Hangzhou Coco Healthcare Products Co., Ltd. Class A holds 916.31M in cash and equivalents against 268.71M in total debt, resulting in a net debt position of -215.20M. Total book value stands at 1.30B, with working capital of 590.19M providing operational flexibility.

Cash & Cash Equivalents916.31M
Total Debt268.71M
Net Debt-215.20M
Equity (Book Value)1.30B
Book Value Per Share4.77
Working Capital590.19M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-105.95M

Margins

Over the twelve months ended September 30, 2026, Hangzhou Coco Healthcare Products Co., Ltd. Class A posted a gross margin of 23.45, reflecting its pricing power and cost economics. The operating margin of 1.70 and net profit margin of -0.41 provide insight into operational efficiency.

Gross Margin23.45
Operating Margin1.70
Pretax Margin-0.73
Profit Margin-0.41
EBITDA Margin-0.60

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hangzhou Coco Healthcare Products Co., Ltd. Class A paid dividends of 0.13 per share. The dividend payout ratio of -2,595.50 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.82, meaning Hangzhou Coco Healthcare Products Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.13
Payout Ratio-2,595.50
Shareholder Yield-0.82

Scores

As of September 30, 2026, Hangzhou Coco Healthcare Products Co., Ltd. Class A has an Altman Z-Score of 2.90, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.90